Mueller Raeghan L, Hooper Jake F, Ellingson Jarrod M, Olsavsky Aviva K, Rzasa-Lynn Rachael, Bryan Angela D, Bidwell L Cinnamon, Hutchison Kent E
Department of Psychiatry, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.
Children's Hospital Colorado, Aurora, CO, United States.
Front Psychiatry. 2025 Apr 28;16:1516351. doi: 10.3389/fpsyt.2025.1516351. eCollection 2025.
Cannabidiol (CBD) has recently gained attention for its potential therapeutic effects in substance use disorders, including Alcohol Use Disorder (AUD). This study examined the potential therapeutic effects of commercially available products containing CBD with and without a small amount of tetrahydrocannabinol (THC) on alcohol use and craving among individuals with moderate to severe AUD.
In this feasibility study, a total of 44 participants were randomized to one of three conditions: full-spectrum CBD ( = 13, fsCBD - <0.3% THC), broad-spectrum CBD ( = 15, bsCBD - without THC), or placebo control ( = 16) for 8 weeks. The study was designed to assess the safety and tolerability of these treatments and to evaluate whether CBD demonstrated any clinical effects (Clinicaltrials.gov Identifier: NCT04873453; https://clinicaltrials.gov/study/NCT04873453). It was hypothesized that both CBD conditions would be well tolerated and would reduce drinking, alcohol dependence, and craving compared to placebo.
Analyses of attrition and side effect data indicated no significant differences across conditions, suggesting that both bsCBD and fsCBD were well tolerated. Individuals receiving fsCBD demonstrated reductions in craving but no reduction in drinks per drinking day.
In this pilot study, safety profiles fsCBD and bsCBD were similar, and fsCBD was associated with a greater reduction in craving and AUD symptoms relative to both bsCBD and placebo. Future studies with larger sample sizes will be necessary to replicate and extend these findings by addressing the question of whether a small amount of THC may work synergistically with CBD.
大麻二酚（CBD）最近因其在物质使用障碍，包括酒精使用障碍（AUD）中的潜在治疗作用而受到关注。本研究调查了含有CBD且含有或不含有少量四氢大麻酚（THC）的市售产品对中度至重度酒精使用障碍患者的酒精使用和渴望的潜在治疗作用。
在这项可行性研究中，共有44名参与者被随机分为三个组之一：全谱CBD组（n = 13，fsCBD - THC含量<0.3%）、广谱CBD组（n = 15，bsCBD - 不含THC）或安慰剂对照组（n = 16），为期8周。该研究旨在评估这些治疗方法的安全性和耐受性，并评估CBD是否具有任何临床效果（Clinicaltrials.gov标识符：NCT04873453；https://clinicaltrials.gov/study/NCT04873453）。假设与安慰剂相比，两种CBD组的耐受性良好，并且会减少饮酒、酒精依赖和渴望。
对损耗和副作用数据的分析表明，各组之间没有显著差异，这表明bsCBD和fsCBD的耐受性都很好。接受fsCBD的个体渴望程度降低，但每日饮酒量没有减少。
在这项初步研究中，fsCBD和bsCBD的安全性概况相似，并且相对于bsCBD和安慰剂，fsCBD与更大程度地减少渴望和酒精使用障碍症状相关。未来需要进行更大样本量的研究，通过解决少量THC是否可能与CBD协同作用的问题来复制和扩展这些发现。
